Dr. Szalat is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
830 Harrison Avenue 3rd FL
Moakley Bldg
Boston, MA 02118Phone+1 617-638-6428Fax+1 617-638-5756
Summary
- I am specialized in clinical immunology and hematology, translational and genomics research. After 5 years at the DFCI/Harvard Medical school as a research fellow, working on multiple myeloma biology, I am now back in the clinic as a clinical fellow at Boston Medical Center/Boston University in hematology oncology. I did my medical training in Paris, France at the assistance publique des hopitaux de Paris (APHP) in internal medicine and Immunology-hematology. I specialized in clinical Immunology and I have a Master in Immunology from Paris Descartes and the Pasteur Institute and a PhD in Hematology from Paris La Sorbonne. During my training, I participated as a co-investigator to several clinical trials and I am looking forward on continuing working on plasma cells disorders and lymphoid malignancies.
Education & Training
Paris VI University School of MedicineClass of 2004
Certifications & Licensure
MA State Medical License 2018 - 2026
Publications & Presentations
PubMed
- Febrile neutropenia in patients with Duffy-null-associated neutrophil counts and multiple myeloma or AL amyloidosis.Maya Abdallah, Frances Arters, Jasmine Patel, Camille Edwards, Adam Lerner
Blood Advances. 2024-12-10 - 3 citationsGraded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis.Eli Muchtar, Brendan Wisniowski, Susan Geyer, Giovanni Palladini, Paolo Milani
JAMA Oncology. 2024-10-01 - 3 citationsRole of minimal residual disease assessment in multiple myeloma.Raphael Szalat, Kenneth Anderson, Nikhil Munshi
Haematologica. 2024-07-01
Abstracts/Posters
- Favorable Progression-Free Survival Associated with Immune Bio-Markers Modulated By Pomalidomide in Relapsed/Refractory Multiple Myeloma: An Analysis of Phase III StudyRaphael Szalat, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Lectures
- Chromatin Accessibility Profiling Reveals Cis-Regulatory Heterogeneity and Novel Transcription Factor Dependencies in Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- The Landscape of Structural Variant Signatures in Multiple Myeloma Identifies Distinct Disease Subgroups with Implications for Pathogenesis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Inhibitor of DNA Binding 2 (ID2) Plays a Key Tumor Suppressor Role in Promoting Oncogenic Transformation in Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
Emerging Therapies for Multiple MyelomaMay 30th, 2019- Recent FDA Rulings on Multiple Myeloma TreatmentsApril 4th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
